{"id":"bms-986165-dose-b","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":{"chemblId":"CHEMBL4596392","moleculeType":"Small molecule","molecularWeight":"422.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, BMS-986165 allows T cells to recognize and attack cancer cells more effectively. This mechanism is thought to be responsible for its anti-tumor activity. The exact molecular details of this interaction are complex and involve multiple protein-protein interactions.","oneSentence":"BMS-986165 is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:08.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT06869551","phase":"PHASE3","title":"A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-03-13","conditions":"Juvenile Psoriatic Arthritis","enrollment":60},{"nctId":"NCT06566768","phase":"PHASE1","title":"Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-10-07","conditions":"Healthy Participants","enrollment":52},{"nctId":"NCT04167462","phase":"PHASE3","title":"An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-25","conditions":"Psoriasis","enrollment":220},{"nctId":"NCT04949269","phase":"PHASE1","title":"A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-20","conditions":"Healthy Participants","enrollment":61},{"nctId":"NCT03881059","phase":"PHASE2","title":"Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-04-01","conditions":"Active Psoriatic Arthritis","enrollment":203},{"nctId":"NCT04536961","phase":"PHASE1","title":"A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-09-10","conditions":"Healthy Volunteers","enrollment":56},{"nctId":"NCT04209699","phase":"PHASE1","title":"A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-12-27","conditions":"Healthy Participants","enrollment":18},{"nctId":"NCT04249284","phase":"PHASE1","title":"Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-02-06","conditions":"Healthy Participants","enrollment":18},{"nctId":"NCT03873415","phase":"PHASE1","title":"Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-01-25","conditions":"Psoriasis","enrollment":9},{"nctId":"NCT02534636","phase":"PHASE1","title":"Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-10","conditions":"Healthy Subjects","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BMS-986165 Dose B","genericName":"BMS-986165 Dose B","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986165 is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}